A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer

The recruitment status of this study is unknown because the information has not been verified recently.
Verified January 2014 by National University Hospital, Singapore.
Recruitment status was  Active, not recruiting
Information provided by:
National University Hospital, Singapore
ClinicalTrials.gov Identifier:
First received: July 20, 2009
Last updated: January 21, 2014
Last verified: January 2014
  1. To determine the association between LVD and clinico-pathologic variables in archived colorectal cancer and Nasopharyngeal carcinoma specimens
  2. To determine the association between VEGF-C,-D expression with COX-2 expression and clinico-pathologic variables in colorectal cancer and Nasopharyngeal carcinoma
  3. To determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma Lymphangiogenesis and factors modulating lymphangiogenesis are associated with clinico-pathological outcome in Nasopharyngeal carcinoma and colorectal cancer. Celecoxib down-regulates lymphangiogenesis Archival colorectal cancer and Nasopharyngeal carcinoma tumor specimens will be obtained from the Department of Pathology. To determine the effect of celecoxib on lymphangiogenesis in Nasopharyngeal carcinoma, the investigators intend to analyze archived specimens collected in a previously conducted study. Colorectal tumor and nodal specimens and Nasopharyngeal carcinoma primary will be examined for MVD, LVD and growth factor expression using established haematoxylin and eosin and immunohistochemical techniques. Quantification of LVD and MVD shall be performed by two pathologists blinded to clinico-pathological variables using standardised methods.

Condition Intervention
Colorectal Cancer
Nasopharyngeal Cancer
Procedure: Tumor biopsies

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Cross-Sectional
Official Title: A Study of Lymphangiogenesis in Colorectal and Nasopharyngeal Cancer

Resource links provided by NLM:

Further study details as provided by National University Hospital, Singapore:

Biospecimen Retention:   Samples With DNA
CRC and NPC tumor specimens will be obtained.

Estimated Enrollment: 500
Study Start Date: July 2008
Estimated Study Completion Date: December 2014
Estimated Primary Completion Date: December 2014 (Final data collection date for primary outcome measure)
Groups/Cohorts Assigned Interventions
Tumor biopsies Procedure: Tumor biopsies


Ages Eligible for Study:   21 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
Colorectal and nasopharyngeal cancer.

Inclusion Criteria:

  • Male and female patients are eligible
  • Patients 21 years or older

Exclusion Criteria:

  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00943891

National University Hospital
Singapore, Singapore, 119074
Sponsors and Collaborators
National University Hospital, Singapore
Principal Investigator: Ross Andrew Soo, MBBS National University Hospital, Singapore
  More Information

ClinicalTrials.gov Identifier: NCT00943891     History of Changes
Other Study ID Numbers: MC01/09/08 
Study First Received: July 20, 2009
Last Updated: January 21, 2014
Health Authority: Singapore: Domain Specific Review Boards

Additional relevant MeSH terms:
Nasopharyngeal Neoplasms
Head and Neck Neoplasms
Nasopharyngeal Diseases
Neoplasms by Site
Otorhinolaryngologic Diseases
Otorhinolaryngologic Neoplasms
Pharyngeal Diseases
Pharyngeal Neoplasms
Stomatognathic Diseases

ClinicalTrials.gov processed this record on May 24, 2016